Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ASV AGEN2017+ QS-21 Stimulon adjuvant · 1 trial · 1 indication
Assessed by monitoring the frequency, duration, and severity of drug-related AEs by completing physical examinations and clinical evaluations; evaluating changes in vital signs; and laboratory blood and urine sample evaluations.
| Arm | Type | Description |
|---|---|---|
| ASV® AGEN2017 | EXPERIMENTAL | ASV® AGEN2017 + QS-21 Stimulon® Adjuvant Vaccine |
| Name | Type | Description |
|---|---|---|
| ASV® AGEN2017 + QS-21 Stimulon® adjuvant | BIOLOGICAL | Neoantigen Vaccine |
Inclusion Criteria: 1. Signed, written informed consent. 2. Age ≥18 years. 3. Diagnosis of solid cancer that has been completely resected, NED, and eligible for observation only as SOC yet remain at risk of relapse per Investigator discretion. These include subjects diagnosed with malignant melanom...
ASV AGEN2017+ QS-21 Stimulon adjuvant is an investigational monoclonal antibody therapeutic being developed by Agenus Inc. for the treatment of adult patients with solid tumors. It combines the ASV AGEN2017 antibody component with the QS-21 Stimulon adjuvant, a formulation intended to be evaluated in oncology settings.
ASV AGEN2017+ QS-21 Stimulon adjuvant is being studied for use in adults with solid tumors. Its only recorded clinical study enrolled patients with solid tumors, and the program remains in early clinical development rather than approved clinical use.
Agenus Inc., which trades under the ticker AGEN, is the developer of ASV AGEN2017+ QS-21 Stimulon adjuvant. The company is responsible for the investigational monoclonal antibody program and its QS-21 Stimulon adjuvant combination.
ASV AGEN2017+ QS-21 Stimulon adjuvant is in Phase 1 development. It is investigational and has not been approved for commercial use. The program's single recorded trial was a Phase 1a study that has since been completed.
ASV AGEN2017+ QS-21 Stimulon adjuvant was evaluated in one clinical trial, NCT03673020, titled a Phase 1a Study to Evaluate Immunogenicity of ASV. That trial enrolled 3 adult patients with solid tumors in the United States and is now completed, with no active trials currently listed.